C. Frank Bennett

C. Frank Bennett is an American scientist known for his contributions to the field of genetics and neuroscience. He is a co-founder and the Senior Vice President of Research at Ionis Pharmaceuticals, a biotechnology company specializing in the development of antisense oligonucleotide therapies.

Early Life and Education

Bennett received his B.S. degree in Pharmacy from the University of New Mexico. He then went on to earn his Ph.D. in Pharmacology from the University of Pennsylvania.

Career

Bennett began his career in the pharmaceutical industry, focusing on the development of novel therapeutic approaches. In 1989, he co-founded Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals), where he has played a pivotal role in advancing the company's research and development efforts.

Contributions to Science

Bennett is widely recognized for his work in the development of antisense oligonucleotides, a class of drugs designed to target and regulate the expression of specific genes. His research has led to the development of several FDA-approved therapies, including Spinraza (nusinersen), the first treatment for spinal muscular atrophy (SMA).

Antisense Oligonucleotides

Antisense oligonucleotides are short, synthetic strands of nucleic acids that can bind to RNA molecules, modulating their function. This technology has been applied to treat a variety of genetic disorders, including Huntington's disease, amyotrophic lateral sclerosis (ALS), and Duchenne muscular dystrophy.

Awards and Honors

Bennett has received numerous awards for his contributions to medical science, including the Oligonucleotide Therapeutics Society Lifetime Achievement Award and the American Chemical Society's Heroes of Chemistry Award.

Personal Life

Bennett resides in California and continues to be actively involved in research and development at Ionis Pharmaceuticals.

See Also

• Ionis Pharmaceuticals
• Antisense therapy
• Spinraza
• Spinal muscular atrophy